How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

Incyte Corporation, a Wilmington-based biopharmaceutical company, has demonstrated solid stock performance relative to the broader biotech sector in recent trading periods. The company discovers, develops, and commercializes treatments for cancer, blood disorders, and immune-mediated diseases, with marketed therapies including JAKAFI for blood cancer, ICLUSIG for leukemia, PEMAZYRE for bile-duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. The company’s market